Your browser is no longer supported. Please, upgrade your browser.
Settings
XBIT XBiotech Inc. daily Stock Chart
XBIT [NASD]
XBiotech Inc.
Index- P/E1.24 EPS (ttm)9.24 Insider Own51.60% Shs Outstand27.48M Perf Week17.13%
Market Cap315.75M Forward P/E57.45 EPS next Y0.20 Insider Trans-10.49% Shs Float9.27M Perf Month0.00%
Income668.60M PEG- EPS next Q0.06 Inst Own19.80% Short Float31.66% Perf Quarter-38.75%
Sales- P/S- EPS this Y-98.40% Inst Trans-47.81% Short Ratio3.40 Perf Half Y23.42%
Book/sh18.34 P/B0.63 EPS next Y-13.04% ROA268.70% Target Price28.00 Perf Year11.66%
Cash/sh26.00 P/C0.44 EPS next 5Y- ROE288.60% 52W Range6.76 - 26.40 Perf YTD-38.44%
Dividend- P/FCF- EPS past 5Y87.30% ROI- 52W High-56.48% Beta1.10
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low69.95% ATR0.79
Employees60 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)47.03 Volatility6.01% 8.67%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.28 Prev Close10.94
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout0.00% Avg Volume862.86K Price11.49
Recom2.00 SMA2012.98% SMA50-22.20% SMA200-5.64% Volume245,520 Change5.03%
Jun-14-19Initiated Piper Jaffray Overweight $13
Apr-21-17Downgrade Noble Financial Buy → Hold $13
Jun-28-16Reiterated Noble Financial Buy $24 → $30
Apr-03-20 04:53PM  XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients GlobeNewswire +5.03%
Feb-19-20 08:15AM  XBiotech Announces Final Results of Tender Offer GlobeNewswire
Feb-13-20 01:24PM  Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer GlobeNewswire -24.17%
08:15AM  XBiotech Announces Preliminary Results of Tender Offer GlobeNewswire
Feb-10-20 03:59PM  $1.35B deal offers vindication, runway for Austin-based XBiotech American City Business Journals
Jan-15-20 08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
Jan-14-20 08:30AM  XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares GlobeNewswire +30.67%
Dec-30-19 04:05PM  XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen GlobeNewswire
Dec-20-19 02:53PM  XBiotech Inc. (XBIT): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-17-19 08:15AM  XBiotech Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-10-19 07:14AM  Drug manufacturers have spent a record $342 billion on M&A in 2019 MarketWatch
Dec-07-19 03:05AM  XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen GlobeNewswire
Nov-19-19 08:55AM  XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa GlobeNewswire +10.42%
Nov-12-19 08:45AM  XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1 Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema) GlobeNewswire
Oct-23-19 08:15AM  XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa GlobeNewswire
Oct-10-19 02:57PM  XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Oct-02-19 08:59AM  XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis GlobeNewswire -8.48%
Sep-27-19 08:15AM  XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain GlobeNewswire
Sep-20-19 08:15AM  XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies GlobeNewswire
Jul-16-19 01:15PM  What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? Simply Wall St.
Jul-11-19 08:30AM  Dr. Seth Forman to Chair XBiotechs Second Phase 2 Study of Bermekimab in Atopic Dermatitis GlobeNewswire
Jul-10-19 08:00AM  XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board GlobeNewswire
Jul-09-19 08:00AM  Medical Research Council Funds Phase 2 Multi-Center Study of XBiotechs Bermekimab in Advanced Cancer Patients GlobeNewswire
Jun-26-19 08:30AM  XBiotech Wins Commercial Real Estate Award for Industrial Development for its Headquarters in Austin, Texas GlobeNewswire
Jun-25-19 08:45AM  XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa GlobeNewswire
Jun-11-19 08:00AM  XBiotech Added to Russell 3000® Index GlobeNewswire
Jun-04-19 04:01PM  XBiotech Announces Closing of Public Offering of Common Shares GlobeNewswire -5.57%
May-31-19 08:47AM  XBiotech Announces Pricing of Public Offering of Common Shares GlobeNewswire -20.70%
May-30-19 04:32PM  XBiotech Announces Public Offering of Common Shares GlobeNewswire
May-23-19 08:20AM  XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa GlobeNewswire
May-13-19 09:27AM  5 Growthy Biotech Stocks to Buy Despite the Scrutiny InvestorPlace
May-02-19 08:15AM  XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study GlobeNewswire +5.26%
Apr-29-19 07:54AM  Read This Before Selling XBiotech Inc. (NASDAQ:XBIT) Shares Simply Wall St.
Mar-04-19 01:44PM  How you should trade the biotech ETFs CNBC Videos
Mar-01-19 12:54PM  S&P has best two-month start to year since 1991 CNBC Videos +17.78%
11:44AM  Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-07-19 11:19AM  You Should Be Selling XBiotech Stock After the Huge Gains InvestorPlace -8.02%
Feb-06-19 02:20PM  These 4 Biotech Stocks Are Leading The Industry ACCESSWIRE +16.98%
Jan-29-19 08:15AM  Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting GlobeNewswire
Jan-28-19 11:28AM  Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting GlobeNewswire
Jan-23-19 08:30AM  Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain GlobeNewswire
Dec-13-18 08:00AM  XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study GlobeNewswire
Dec-12-18 08:30AM  XBiotechs Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease GlobeNewswire
Dec-03-18 08:15AM  XBiotech Announces Successful Completion of GMP Audit GlobeNewswire
Nov-23-18 07:35AM  Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-31-18 04:05PM  XBiotech Highlights Third Quarter Developments for 2018 GlobeNewswire
Oct-26-18 08:15AM  XBiotech Announces New Patents for Third Quarter 2018 GlobeNewswire
Oct-24-18 10:35AM  XBiotech Announces Dismissal of Securities Class Action Suit GlobeNewswire
Oct-05-18 08:00AM  XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis GlobeNewswire
Sep-26-18 08:00AM  XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases GlobeNewswire
Sep-24-18 08:30AM  XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa GlobeNewswire
Sep-20-18 08:00AM  XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team GlobeNewswire
Sep-13-18 08:00AM  XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis GlobeNewswire
Sep-12-18 08:00AM  XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board GlobeNewswire +26.62%
Aug-27-18 08:00AM  XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks GlobeNewswire
Aug-10-18 08:00AM  XBiotech Highlights Quarterly Developments GlobeNewswire
Jul-10-18 08:01AM  XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa GlobeNewswire
08:00AM  XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa GlobeNewswire
May-22-18 08:01AM  XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis GlobeNewswire
Apr-16-18 08:01AM  XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology GlobeNewswire -5.93%
Apr-02-18 08:01AM  XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer GlobeNewswire
Jan-29-18 07:30AM  Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference ACCESSWIRE
Jan-26-18 08:01AM  XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa GlobeNewswire
Jan-25-18 08:01AM  XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus GlobeNewswire
08:00AM  XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus GlobeNewswire
Jan-22-18 07:20AM  Blog Exposure - XBiotech to Present Phase-2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa at EHSF Conference ACCESSWIRE
Jan-19-18 08:01AM  XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa GlobeNewswire
Dec-11-17 11:18AM  The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc. Business Wire
Dec-04-17 04:15PM  XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology GlobeNewswire
Nov-17-17 03:39PM  The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc. Business Wire
Nov-16-17 06:08PM  Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark Diagnostics, Inc., Impax Laboratories, Inc., RPM International Inc. and XBiotech Inc. PR Newswire
Nov-14-17 07:31AM  XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions GlobeNewswire
Nov-08-17 02:30PM  XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc. Business Wire
Nov-03-17 12:18PM  XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions GlobeNewswire
11:54AM  XBiotechs MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions GlobeNewswire
09:36AM  XBIT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc. Business Wire
Nov-02-17 04:42PM  IMPORTANT XBIOTECH, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas on behalf of investors who purchased and suffered losses in XBiotech, Inc. GlobeNewswire
Oct-26-17 02:54PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBIT GlobeNewswire
Oct-19-17 11:57AM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT ACCESSWIRE
Oct-18-17 10:41AM  XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer GlobeNewswire
Oct-03-17 08:00AM  XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board GlobeNewswire
Sep-21-17 08:01AM  XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference GlobeNewswire
Sep-20-17 08:00AM  XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer GlobeNewswire
Sep-18-17 06:16PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. Business Wire
Sep-07-17 08:00AM  XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa GlobeNewswire
Jul-11-17 12:25PM  Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action Business Wire
Jun-22-17 04:37PM  Stocks close mostly lower as financials, consumer staples weigh MarketWatch
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool
Jun-13-17 08:00AM  Today's Research Reports on Stocks to Watch: Xbiotech and GTx Accesswire
Jun-12-17 09:22AM  Biotech Movers: Coherus, XBiotech, Flexion TheStreet.com
Jun-09-17 03:32PM  XBiotech's stock plunges after IDMC recommends ending late-stage trial of colorectal cancer treatment MarketWatch
03:12PM  XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis GlobeNewswire
03:04PM  XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis GlobeNewswire
Jun-06-17 08:46AM  Why XBiotech Inc. (XBIT) Could Shock the Market Soon Zacks
Jun-02-17 03:58PM  Why XBiotech Inc Jumped Higher Today Motley Fool
Jun-01-17 08:36AM  XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting GlobeNewswire
08:35AM  XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting GlobeNewswire
May-30-17 08:01AM  Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Ca... GlobeNewswire
08:00AM  Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer GlobeNewswire
May-19-17 09:16AM  Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme TheStreet.com
XBiotech Inc., a pre-market biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is advancing a pipeline of therapies based on harnessing naturally occurring antibodies from patients with immunity to various diseases. Its pipeline consists of product candidates at various stages of development in a range of indications, including oncology, dermatology, peripheral vascular diseases, type 2 diabetes, and infectious diseases. The company's lead product candidate is bermekimab that is in clinical development for therapeutic indications comprising oncology, cardiovascular medicine, and dermatology. Its other product candidates include 514G3, an anti-infective antibody that is in clinical development to treat S. aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development. The company was founded in 2005 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAY STREET FINANCIAL S.A.10% OwnerFeb 19Sale6.381,662,61610,607,4903,337,384Mar 25 10:09 AM
MCKENZIE W THORPEDirectorJan 06Option Exercise3.75123,000461,2503,706,600Jan 09 04:19 PM
MCKENZIE W THORPEDirectorNov 29Option Exercise3.75185,000693,7503,583,600Dec 04 03:29 PM
MCKENZIE W THORPEDirectorSep 06Sale3.697,15926,3973,880,421Sep 06 04:35 PM
RENNES FONDATION10% OwnerJun 04Buy8.251,200,0009,900,0005,110,282Jun 06 10:36 AM